Loading clinical trials...

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden | Clinical Trials | Clareo Health

COMPLETED

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

A Retrospective Database Analysis of Anticholinergic Burden Among the Elderly With and Without Overactive Bladder in Australia and South Korea

NCT03903094•Astellas Pharma Singapore Pte. Ltd.

View on ClinicalTrials.gov

Summary

Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have at least one dispensing of any medication between January 22, 2016 and December 31, 2016.
•Have at least one dispensing of any medication between January 1st, 2016 and December 31, 2016.
•Participant was diagnosed with OAB (ICD-10 N32.8, N31.0, N31.1, N31.2, N31.8, N31.9, N32.9, N39.8 and N39.40) at index date.
•Participant did not have dispensing record of an OAB medication during the washout period (6 months prior to the index date).

Exclusion Criteria

•Participants who do not have a complete year of data availability in the database prior to index date.
•Have record of hospitalization on the index date.
•Participant was hospitalized on the index date.
•Participant did not have an active insurance status during the washout period or on the index date.
•Participant received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment during the washout period.
•Participant was diagnosed with stress incontinence (ICD-10 N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) during the washout period.
•Participant was diagnosed with urinary tract infection (ICD-10 N30.0 and N39.0 or equivalent) during the washout period or on the index date.

Locations (2)

Site AU61001

Melbourne, Australia

Site KR82001

Seoul, South Korea

Key Dates

Start Date

March 7, 2019

Primary Completion Date

May 6, 2022

Completion Date

May 6, 2022

Last Updated

October 31, 2024

Enrollment

6,295,279

ACTUAL participants

Conditions

Overactive Bladder (OAB)

Interventions

Non-Interventional

OTHER

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07193407

Overactive Bladder (OAB)

View study

RECRUITINGNA

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07195656

Overactive Bladder (OAB)

View study

ENROLLING_BY_INVITATIONNA

Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

NCT06765629

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 31, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Inclusion Criteria

Exclusion Criteria

INOPASE - Performance and Safety Study of a Personalised SNM System

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

Tensi+ for Treating Overactive Bladder: A Randomized Controlled Trial

BlueWind RENOVA iStim™ System for the Treatment of OAB